Skip to content
Screener

BridgeBio Pharma BBIO Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$154.49M+16.3%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$5.7M-6.9%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
LQD
Liquidia CorporationLQDA
$6.96M+1.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.5M-5.6%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$12.87M+29.2%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.22B+89.3%
Enterprise value$18.6B+138%
P/S28×-8.4×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001743881-26-000019
Line itemAmountAmount
Thereafter4,684
Total future minimum lease payments23,455
Imputed interest(4,800)
Total$$18,655
Reported as of March 31, 2026
Operating lease liabilities, current portion$$4,439
Operating lease liabilities, net of current portion14,216
Total operating lease liabilities$$18,655

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's operating lease liabilities (total)?
BridgeBio Pharma (BBIO) reported operating lease liabilities (total) of $18.66M in Q1 2026.
How has BridgeBio Pharma's operating lease liabilities (total) changed year-over-year?
BridgeBio Pharma's operating lease liabilities (total) increased by 84.3% year-over-year, from $10.12M to $18.66M.
What is the long-term trend for BridgeBio Pharma's operating lease liabilities (total)?
Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease liabilities (total) has grown at a -11.5% compound annual growth rate (CAGR), from $18.47M to $10M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about BridgeBio Pharma's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude